Related Experiment Video
Updated: Jul 29, 2026
Visualization and Analysis of Blood Flow and Oxygen Consumption in Hepatic Microcirculation: Application to an Acute Hepatitis Model
Published on: August 4, 2012
Anticoagulant therapy for sepsis-associated disseminated intravascular coagulation: the view from Japan
1Department of Emergency and Disaster Medicine, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
Insights
Anticoagulant therapy shows promise for sepsis-related disseminated intravascular coagulation (DIC) due to anti-inflammatory effects. Further large-scale trials are needed to confirm optimal use in treating this critical condition.
Area of Science:
- Hematology
- Critical Care Medicine
- Pharmacology
Background:
- Current disseminated intravascular coagulation (DIC) management focuses on treating the underlying cause and blood product resuscitation.
- Anticoagulant therapy's role in DIC treatment has varied across guidelines, with some agents removed due to insufficient evidence.
- Emerging evidence highlights the interplay between coagulation and inflammation in sepsis, involving neutrophil extracellular traps and damage-associated molecular patterns (DAMPs).
Purpose of the Study:
- To review the role of anticoagulants in sepsis-related DIC.
- To examine clinical studies on specific anticoagulants like antithrombin, recombinant thrombomodulin, and activated protein C.
- To discuss the potential benefits of anticoagulants beyond their anticoagulant effects, including anti-inflammatory properties.
Main Methods:
- Literature review of clinical studies and guidelines concerning DIC and anticoagulant therapy.
- Analysis of the mechanisms involving coagulation, inflammation, DAMPs, and natural anticoagulants in sepsis.
- Detailed examination of studies investigating antithrombin, recombinant thrombomodulin, and plasma-derived activated protein C in sepsis-related DIC.
Main Results:
- Anticoagulants may offer benefits in sepsis-related DIC due to their anti-inflammatory actions.
- Natural anticoagulants play a role in neutralizing DAMPs and histones implicated in sepsis-induced coagulopathy.
- Clinical studies on specific agents show potential, but require further large-scale randomized controlled trials.
Conclusions:
- Anticoagulant therapy is a potential adjunct in managing sepsis-related DIC, particularly due to anti-inflammatory effects.
- Further research, including large-scale randomized controlled trials, is essential to establish optimal timing, dosage, and duration of anticoagulant treatment.
- Understanding the complex interactions between coagulation and inflammation is key to refining DIC management strategies.
Abstract:
The current management of disseminated intravascular coagulation (DIC) is based on aggressive treatment of the underlying condition and resuscitation with appropriate blood products. Anticoagulant therapy has appeared and disappeared in the different guidelines and important documents detailing the treatment of DIC. For example, Surviving Sepsis Campaign (SSC) guidelines, the 'global standard' for the management of severe sepsis, had recombinant activated protein C highly recommended in the original version, but this was withdrawn in the latest version due to the lack of evidence. In contrast, recent international guidance released from the International Society on Thrombosis and Haemostasis has introduced the potential efficacy of other agents. In sepsis-related DIC, the basis for anticoagulant therapy comes from the mounting evidence for the anti-inflammatory effects which these agents possess and can prove beneficial in septic situations. Several studies have clearly shown the important cross-talk between coagulation and inflammation in patients with sepsis. More recently, neutrophil extracellular traps and damage-associated molecular patterns (DAMPs), especially histones, have been demonstrated to play a crucial role in the coagulopathy of sepsis. Once again, the natural anticoagulants have an important function in neutralizing the effects of DAMPs and histones. In this review, in addition to examining the important role of anticoagulants in the septic milieu, the clinical studies examining antithrombin, recombinant thrombomodulin and plasma-derived activated protein C are detailed. However, large-scale randomized controlled trials are yet to be performed, with important consideration of the timing, dosage and duration of treatment.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:18Endocarditis III: Medical Management
01:29Venous Thrombosis III: Interprofessional Care
01:30Venous Thrombosis IV: Nursing Management
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care